| abstract |
The present invention relates to the field of minimal residual disease (MRD) diagnostics, which are increasingly used to evaluate the efficacy of treatment in patients with hematological malignancies, such as B-cell precursor acute lymphoblastic leukemia (BCP-ALL), B-cell chronic lymphocytic Cellular leukemia (B-CLL) and multiple myeloma (MM). The unique reagent composition offered features carefully selected and thoroughly tested antibody combinations that can reach at least 10 -4 and even as low as Sensitivity of 10 -5 . The invention also provides diagnostic kits and methods for detecting MRD. |